Bedell Frazier Investment Counselling’s Vertex Pharmaceuticals VRTX Stock Holding History

Bedell Frazier Investment Counselling’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-39,770	Closed	-$4.72M	–	80
2014 Q4	$4.72M	Sell	39,770 -28,318	-42%	-$3.19M	2.32%	17
2014 Q3	$7.65M	Buy	68,088 +524	+0.8%	+$49.9K	3.57%	5
2014 Q2	$6.4M	Buy	67,564 +450	+0.7%	+$31.6K	3.24%	7
2014 Q1	$4.75M	Buy	67,114 +50	+0.1%	+$3.96K	2.66%	18
2013 Q4	$4.98M	Buy	67,064 +525	+0.8%	+$36.6K	2.34%	14
2013 Q3	$5.04M	Buy	66,539 +655	+1%	+$52.1K	2.42%	15
2013 Q2	$5.1M	Buy	+65,884	New	+$4.85M	2.53%	13

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bedell Frazier Investment Counselling's VRTX Position: Q1 2015 in Review

Bedell Frazier Investment Counselling sold out of Vertex Pharmaceuticals (VRTX) in Q1 2015, closing a stake of 39,770 shares — an estimated $4.72M sold.

Bedell Frazier Investment Counselling first reported a position in VRTX in Q2 2013 and held it in 7 quarters. The position peaked at $7.65M in Q3 2014. 480 funds tracked by Wall St. Rank hold VRTX as of Q1 2015.

Bedell Frazier Investment Counselling reported no remaining Vertex Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Bedell Frazier Investment Counselling sold 39,770 Vertex Pharmaceuticals shares in Q1 2015, an estimated $4.72M.
Bedell Frazier Investment Counselling first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Bedell Frazier Investment Counselling's Vertex Pharmaceuticals position peaked at $7.65M in Q3 2014.
480 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2015.

Based on Bedell Frazier Investment Counselling's 13F filing for Q1 2015, filed 13 May 2015.